फलो गर्नुहोस्
Englishनेपाली
← पछाडि
Anti-Infective Medicines

Oseltamivir

Anti-Infective Medicines
Capsule · Powder30 mg · 45 mg · 75 mg · 6 mg२ ब्रान्ड उत्पादन
Oseltamivir नेपालको National List of Essential Medicines (NLEM, Sixth Revision 2021) मा रहेको औषधि हो। यो Anti-Infective Medicines > 6.4.3 Other antivirals वर्गमा पर्छ। NepalDoc औषधि सूचीमा यसका २ वटा ब्रान्ड उत्पादन छन्।
सामान्य नाम (Generic name)oseltamivir
वर्ग (Therapeutic class)Anti-Infective Medicines > 6.4.3 Other antivirals
रूप र शक्ति (Form & strength, NLEM)Capsule: 30 mg,45 mg, 75 mg (as phosphate); Oral powder: 6 mg/ ml
स्रोतNational List of Essential Medicines Nepal (2021); NepalDoc medicine catalog
स्रोतU.S. FDA-approved label via DailyMed (label effective 15 May 2024) · National List of Essential Medicines, Nepal (2021) · अमेरिकी लेबलिङ नेपालको DDA-स्वीकृत लेबलिङ र स्थानीय प्रिस्क्राइबिङ अभ्यासभन्दा फरक हुन सक्छ।

What it's for

Oseltamivir phosphate for oral suspension is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. Prophylaxis of influenza A and B in patients 1 year and older.

From the U.S. FDA-approved label for Oseltamivir. Full label: DailyMed.

Oseltamivir phosphate for oral suspension is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. Prophylaxis of influenza A and B in patients 1 year and older.

From the U.S. FDA-approved label for Oseltamivir. Full label: DailyMed.

Treatment of influenza Adults and adolescents (13 years and older): 75 mg twice daily for 5 days Pediatric patients 1 to 12 years of age: Based on weight twice daily for 5 days Pediatric patients 2 weeks to less than 1 year of age: 3mg/kg twice daily for 5 days Renally impaired adult patients (creatinine clearance >30 to 60 mL/min): Reduce to 30 mg twice daily for 5 days Renally impaired adult patients (creatinine clearance >10 to 30 mL/min): Reduce to 30 mg once daily for 5 days ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after every hemodialysis cycle.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Oseltamivir phosphate for oral suspension is contraindicated in patients with known serious hypersensitivity to oseltamivir or any component of the product. Severe allergic reactions have included anaphylaxis and serious skin reactions including toxic epidermal necrolysis, Stevens-Johnson Syndrome, and erythema multiforme. Patients with known serious hypersensitivity to oseltamivir or any of the components of oseltamivir phosphate for oral suspension

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Serious skin/hypersensitivity reactions such as Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme: Discontinue oseltamivir phosphate for oral suspension and initiate appropriate treatment if allergic-like reactions occur or are suspected. Neuropsychiatric events: Patients with influenza, including those receiving oseltamivir phosphate for oral suspension, particularly pediatric patients, may be at an increased risk of confusion or abnormal behavior early in their illness. Monitor for signs of abnormal behavior.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following serious adverse reactions are discussed below and elsewhere in the labeling: Serious skin and hypersensitivity reactions Neuropsychiatric events Most common adverse reactions (> 1% and more common than with placebo): Treatment studies – Nausea, vomiting, headache. Prophylaxis studies – Nausea, vomiting, headache, pain. To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc.

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

2 products from 1 maker in the NepalDoc medicine catalog use this generic:

BrandCompositionMakerPack
ANTIFLU 75MG CapsuleOseltamivir (75MG)Cipla Ltd.
Antiful 75mg CapsuleOseltamivir (75mg)Cipla Ltd.

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Store dry powder at 20º to 25ºC (68º to 77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). Preserved in well closed container. Store constituted oral suspension under refrigeration for up to 17 days at 2º to 8ºC (36º to 46ºF). Do not freeze.

Storage information from the U.S. FDA-approved label.

Browse A–Z5ABCDEFGHIJKLMNOPQRSTUVWXYZ

अन्तरक्रिया (Interactions)

अन्य औषधि, खाना र जडीबुटी उत्पादनले Oseltamivir को काम बदल्न सक्छन्। Oseltamivir को FDA लेबलले यसको अन्तरक्रिया खण्डमा ६ अन्य औषधिको नाम लिएको छ।

Oseltamivir का अन्तरक्रिया हेर्नुहोस् →

एपमा औषधि खोज्नुहोस् फार्मेसी खोज्नुहोस्
+ सुरक्षा जानकारी

यो पृष्ठ सामान्य जानकारीका लागि मात्र हो, चिकित्सकीय सल्लाह होइन। औषधि प्रयोग गर्नुअघि डाक्टर वा फार्मासिस्टसँग सल्लाह लिनुहोस्। विवरण माथि उल्लेखित स्रोतहरूबाट आएको हो र परिवर्तन हुन सक्छ। NLEM सूचीमा हुनुले कुनै फार्मेसीमा औषधि उपलब्ध छ भन्ने ग्यारेन्टी दिँदैन।

यो औषधि सेयर गर्नुहोस्
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.